vs
艾伯维（ABBV）与AC Immune SA（ACIU）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是AC Immune SA的11567.6倍（$16.6B vs $1.4M）。艾伯维净利率更高（10.9% vs -1622.4%，领先1633.4%）。AC Immune SA同比增速更快（90.1% vs 10.0%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
ABBV vs ACIU — 直观对比
营收规模更大
ABBV
是对方的11567.6倍
$1.4M
营收增速更快
ACIU
高出80.1%
10.0%
净利率更高
ABBV
高出1633.4%
-1622.4%
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.4M |
| 净利润 | $1.8B | $-23.3M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | -1484.5% |
| 净利率 | 10.9% | -1622.4% |
| 营收同比 | 10.0% | 90.1% |
| 净利润同比 | 8354.5% | 6.9% |
| 每股收益（稀释后） | $1.02 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVACIU
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.4B | $1.4M | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | $755.7K | ||
| Q1 24 | $12.3B | — |
净利润ABBVACIU
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $938.0M | $-23.3M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | $-25.0M | ||
| Q1 24 | $1.4B | — |
毛利率ABBVACIU
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVACIU
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | -1484.5% | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | -3051.1% | ||
| Q1 24 | 22.7% | — |
净利率ABBVACIU
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 6.1% | -1622.4% | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | -3313.0% | ||
| Q1 24 | 11.1% | — |
每股收益（稀释后）ABBVACIU
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.72 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.77 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $28.3M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $82.2M |
| 总资产 | $134.0B | $209.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVACIU
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | $28.3M | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $13.2B | $56.7M | ||
| Q1 24 | $18.1B | — |
总债务ABBVACIU
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVACIU
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | — | ||
| Q2 25 | $-183.0M | $82.2M | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.8B | $135.8M | ||
| Q1 24 | $8.0B | — |
总资产ABBVACIU
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | — | ||
| Q2 25 | $137.2B | $209.2M | ||
| Q1 25 | $136.2B | — | ||
| Q4 24 | $135.2B | — | ||
| Q3 24 | $143.4B | — | ||
| Q2 24 | $141.9B | $261.3M | ||
| Q1 24 | $148.9B | — |
负债/权益比ABBVACIU
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | — |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVACIU
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $4.0B | — |
自由现金流ABBVACIU
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
自由现金流率ABBVACIU
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
资本支出强度ABBVACIU
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率ABBVACIU
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
